OptiBiotix Signs Major Supply Agreement for its Microbiome Modulating Cholesterol-Reduction Probiotic

d6d4fdd0-bcf5-4480-8f73-4ee148db27dbarticleimage.jpg

19 Jun 2017 --- Life sciences company OptiBiotix has signed a three-year supply agreement with HLH BioPharma Vertriebs GmbH for its cholesterol-reducing LPLDL probiotic supplement. Research into the LPLDL probiotic, presented at Vitafoods Europe in May 2017, demonstrated that it is a safe natural ingredient which reduces blood pressure and cholesterol, key determinates of cardiovascular risk. 

According to the company, the probiotic was found to reduce LDL cholesterol by up to 13.9%, and blood pressure by 5.1%. This research was carried out by Glenn Gibson, Professor of Food Microbiology, Head of Food Microbial Sciences at University of Reading.

Stephen O’Hara, CEO of OptiBiotix, comments, “The development of our LPLDL probiotic product has made cholesterol reduction through microbiome modulation a reality, and we are thrilled to be working with HLH, one of Europe’s leading suppliers to the pharmacy market, on this product. The ability to create designer active ingredients which can modify an individual’s microbiome to improve health places OptiBiotix at the forefront of global microbiome research and product development, and we anticipate many more opportunities for the LPLDL probiotic.”

Microbiome modulators in the form of probiotic supplements, like LPLDL, may be the way forward for managing long-term conditions like cardiovascular disease (CVD). The reduction of both LDL cholesterol and blood pressure is key for managing the risk of CVD. The combination of high blood pressure and cholesterol deposition may lead to the chronic inflammation and hardening of the walls of the blood vessels, which greatly increases the probability of suffering a cardiovascular event. Recent research, presented at the European Society of Cardiology Congress 2016, demonstrated that reducing LDL cholesterol and blood pressure can reduce the lifetime risk of cardiovascular disease by nearly 90%.

The supply agreement grants HLH a non-exclusive license to produce, package, and commercialize products containing the LPLDL strain, and follows HLH’s recent order for 100,000 units of LPLDL. HLH has over 20 years’ experience in the distribution of probiotic and natural products under the brand names Lactobact and Casa Sana and is one of Europe’s leading suppliers of probiotics to the pharmacy market. LPLDL will be supplied as bulk capsules which will be packaged and branded as part of HLH’s market leading Lactobact brand.

Related Articles

Nutrition & Health News

Dietary Carotenoids and Vitamin C Inversely Correlate to Lung Cancer Risk, Study Suggests

29 Jun 2017 --- A new study has revealed the protective effects of selected carotenoids and vitamin C against lung cancer risks and growth of a different type of carcinoma cells, with the results showing that when compared to low intake of beta-carotene, alpha-carotene, beta-cryptoxanthin, lycopene and vitamin C, subjects with highest intake of aforementioned carotenoids and vitamin C demonstrated reduced risk of lung cancer. 

Food Research

Cheers to That: Researchers Create Gut-Friendly Probiotic Beer

29 Jun 2017 --- Beer lovers may soon have a gut-friendly drink to raise a toast to, thanks to the creation of a novel probiotic sour beer by a team of researchers from the National University of Singapore (NUS). This new specialty beer incorporates the probiotic strain Lactobacillus paracasei L26, which was first isolated from human intestines and can neutralize toxins and viruses, as well as regulate the immune system.

Business News

Lonza Receives Regulatory Approval for the Acquisition of Capsugel

29 Jun 2017 --- Lonza has received all regulatory approvals for the proposed acquisition of Capsugel S.A. by Lonza, the company has announced. With all final regulatory approvals in place, Lonza can now complete the transaction, which is expected to close in the next days subject to the satisfaction of customary closing conditions. 

Nutrition & Health News

FSAI Launches Consultation on Vitamin D Supplements for Infants in Ireland

29 Jun 2017 --- The Food Safety Authority of Ireland (FSAI) today announced that it is holding a public consultation on the criteria for 5µg Vitamin D only supplements to be listed as suitable for infants in Ireland. The online consultation started yesterday and will be held until 11 August. FSAI invites caregivers, health professionals, food supplement manufacturers, food businesses and any other interested parties to take part. This consultation is in the form of a survey which can be found on the FSAI website.

Nutrition & Health News

More than Half of Foods Aimed at Children are Unhealthy, Australian Survey Shows

28 Jun 2017 --- New research by Australia’s Obesity Policy Coalition (OPC) has found that more than half of supermarket products marketed at kids are unhealthy. The OPC surveyed 186 packaged foods with cartoons or character promotions designed to attract children and found that 52 percent were classified as unhealthy by the Food Standards Australia New Zealand (FSANZ) Nutrient Profiling Scoring Criterion calculator, which looks at the amount of energy and certain nutrients (e.g. saturated fat, sugars, sodium) present in the food.

More Articles
URL : http://www.nutritioninsight.com:80/news/optibiotix-signs-major-supply-agreement-for-its-microbiome-modulating-cholesterol-reduction-probiotic.html